GILEAD SCIENCES, INC. (GILD) FY2025 Q1 P&L / Income Statement

GILEAD SCIENCES, INC. (GILD) FY2025 Q1 P&L / Income Statement

Income statement for 2025-01-01 through 2025-03-31. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

6,667,000,000 US dollars

Cost of goods sold

1,540,000,000 US dollars

Gross profit (calculated)

5,127,000,000 US dollars

Operating expenses (calculated)

2,890,000,000 US dollars

Operating income (loss)

2,237,000,000 US dollars

Other income (expense), net (calculated)

negative 588,000,000 US dollars

Income (loss) before income taxes

1,649,000,000 US dollars

Income tax expense (benefit)

334,000,000 US dollars

Net income (loss)

1,315,000,000 US dollars

Tecartus

78,000,000 US dollars

Yescarta

386,000,000 US dollars

Biktarvy

3,150,000,000 US dollars

Descovy

586,000,000 US dollars

Genvoya

364,000,000 US dollars

Odefsey

281,000,000 US dollars

Symtuza - Revenue share

114,000,000 US dollars

Other HIV

91,000,000 US dollars

Sofosbuvir/Velpatasvir

346,000,000 US dollars

Vemlidy

252,000,000 US dollars

Other Liver Disease

161,000,000 US dollars

Trodelvy

293,000,000 US dollars

AmBisome

139,000,000 US dollars

Other

70,000,000 US dollars

Royalty, contract and other revenues

54,000,000 US dollars

Veklury

302,000,000 US dollars

Selling, general and administrative expenses

1,258,000,000 US dollars

Acquired in-process research and development expenses

253,000,000 US dollars

Research and development expenses

1,379,000,000 US dollars

In-process research and development impairments

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.